Completed OBSERVATIONAL NCT01125605

PASCONAL NERVENTROPFEN in the Treatment of Nervous Diseases (174)

PASCONAL NERVENTROPFEN in the Treatment of Adults and Children Suffering From Nervous Diseases (e.g. Sleep Disorders Due to Nervousness)

Sponsor: Pascoe Pharmazeutische Praeparate GmbH

Conditions Nervousness Sleep Disorders

Updated 9 times since 2017 Last updated: Mar 24, 2015 Started: May 31, 2010 Primary completion: Oct 31, 2010 Completion: Oct 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01125605, this observational or N/A phase trial focuses on Nervousness and Sleep Disorders and remains completed. Sponsored by Pascoe Pharmazeutische Praeparate GmbH, it has been updated 9 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2023 — Jul 2024 [monthly]

Completed
Dec 2022 — Jan 2023 [monthly]

Completed

▶ Show 4 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

May 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pascoe Pharmazeutische Praeparate GmbH

Data source: Pascoe Pharmazeutische Praeparate GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• All Over Germany, Germany